Patent application number | Description | Published |
20090123421 | ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS - This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-a and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-a/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity. | 05-14-2009 |
20110046073 | SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING - This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β.receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β.receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided. | 02-24-2011 |
20110250200 | SOLUBLE LYMPHOTOXIN-BETA RECEPTOR FUSION PROTEIN AND METHODS FOR INHIBITING LYMPHOTOXIN BETA-RECEPTOR SIGNALING - This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided. | 10-13-2011 |
20150017155 | AGLYCOSYL ANTI-CD154 (CD40 LIGAND) ANTIBODIES AND USES THEREOF - The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the C | 01-15-2015 |
Patent application number | Description | Published |
20090082802 | Mechanism and Method for Closing an Arteriotomy - Devices and methods for closing an arteriotomy by gripping surfaces of tissue disposed about the arteriotomy, without piercing the tissue, and drawing the gripped tissue together to approximate the edges of the arteriotomy, and, while holding the tissue, applying a more permanent closure to the tissue. | 03-26-2009 |
20100179588 | VASCULAR PUNCTURE CLOSURE SYSTEM WITH GUIDE SHEATH STABILIZER - A guide sheath for use in guiding a vascular puncture closure device to and in registry with a vascular puncture includes a stabilization system having retention wires deployable from the sheath and engageable with the vessel wall. The retention wires pierce the vessel wall at spaced locations, proximally and distally, about the puncture and form anchors to retain the sheath in registry with the puncture. | 07-15-2010 |
20100286725 | Systems and Methods for Closing a Percutaneous Vascular Puncture - A system and method for closing a percutaneous vessel puncture at the conclusion of a vascular catheterization procedure includes placement of an intravascular closure device having a radially and axially expandable tubular membrane and a radially expandable anchor at the distal sad of the membrane. The closure device is placed, by a delivery catheter extending through the puncture site, with its anchor radially expanded in a location upstream of the puncture site to enable the force of a patient's blood flow to deploy the tubular membrane to a proximally extended configuration closing the puncture from within the vessel. | 11-11-2010 |